Literature DB >> 21925005

Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome).

John W Frew1, Dédée F Murrell.   

Abstract

Paraneoplastic pemphigus (PNP) or paraneoplastic autoimmune multiorgan syndrome (PAMS) is a life-threatening autoimmune blistering disease commonly associated with lymphoproliferative neoplasms. This article focuses on current management strategies in PNP/PAMS, and reported instances of their treatment successes and failures. Due to the rarity of the condition and the high rates of treatment failure, no randomized control trials exist to guide the evidence-based treatment of this condition; all evidence to date on the efficacy of therapeutic modalities has been gained from individual case reports, small case series, and expert recommendations.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21925005     DOI: 10.1016/j.det.2011.06.016

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  10 in total

1.  Intra-abdominal inflammatory pseudotumor-like follicular dendritic cell sarcoma associated with paraneoplastic pemphigus: A case report and review of the literature.

Authors:  Jia-Yi Zhuang; Fang-Fei Zhang; Qing-Wen Li; Yong-Feng Chen
Journal:  World J Clin Cases       Date:  2020-07-26       Impact factor: 1.337

Review 2.  Remission of Thymoma on Steroid Therapy in a Patient With Atypical Thymoma-Associated Multiorgan Autoimmunity: A Case Report and Literature Review.

Authors:  Ewa Wrona; Sylwia Dębska-Szmich; Marta Pastuszka; Marcin Braun; Rafał Czyżykowski; Piotr Potemski
Journal:  Front Immunol       Date:  2021-04-29       Impact factor: 7.561

3.  Clinical characteristics and prognosis of patients with Castleman disease in a Chinese hospital: paraneoplastic pemphigus is an independent risk factor.

Authors:  Yibo Hua; Chao Liang; Jie Yang; Luyang Wang; Aimin Xu; Lei Xi; Shangqian Wang; Zengjun Wang
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

Review 4.  Paraneoplastic Pemphigus: Insight into the Autoimmune Pathogenesis, Clinical Features and Therapy.

Authors:  Giovanni Paolino; Dario Didona; Giuseppe Magliulo; Giannicola Iannella; Biagio Didona; Santo Raffaele Mercuri; Elisa Moliterni; Michele Donati; Andrea Ciofalo; Guido Granata; Patricia Ranuzzi; Vincenzo Falasca; Stefano Calvieri
Journal:  Int J Mol Sci       Date:  2017-11-26       Impact factor: 5.923

5.  Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab.

Authors:  Yuta Ito; Shinichi Makita; Akiko Miyagi Maeshima; Shunsuke Hatta; Tomotaka Suzuki; Sayako Yuda; Suguru Fukuhara; Wataru Munakata; Tatsuya Suzuki; Dai Maruyama; Koji Izutsu
Journal:  Intern Med       Date:  2018-03-09       Impact factor: 1.271

Review 6.  Paraneoplastic Pemphigus: Paraneoplastic Autoimmune Disease of the Skin and Mucosa.

Authors:  Jong Hoon Kim; Soo-Chan Kim
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

7.  Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview.

Authors:  Celina Wakisaka Maruta; Denise Miyamoto; Valeria Aoki; Ricardo Gomes Ribeiro de Carvalho; Breno Medeiros Cunha; Claudia Giuli Santi
Journal:  An Bras Dermatol       Date:  2019-10-17       Impact factor: 1.896

Review 8.  Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors.

Authors:  Piyu Parth Naik
Journal:  J Transl Autoimmun       Date:  2022-04-16

9.  Paraneoplastic Pemphigus with Underlying Castleman's Disorder: A Rare Report with Literature Review.

Authors:  Syed Hamza Bin Waqar; Anosh Aslam Khan; Osama Mohiuddin; Aiman Rehan
Journal:  Cureus       Date:  2019-06-28

10.  Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies.

Authors:  Lei Cao; Fei Wang; Xin-Yi Du; Hua-Yuan Zhu; Li Wang; Wei Xu; Jian-Yong Li; Lei Fan
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.